In secondary cases, treatment of the cause, where possible, is indicated. Additionally, treatment for<unk>  itself is usually required. While optimal treatment of<unk>  is still being debated, current treatment regimes usually involve high dose corticosteroids, etoposide and cyclosporin. Intravenous immunoglobulin is also used. Methotrexate and vincristine have also been used. Other medications include cytokine targeted therapy. On 20 November 2018, the FDA approved the anti-IFN-gamma monoclonal antibody emapalumab (proprietary name Gamifant) for the treatment of pediatric and adult primary<unk> . In October 2021 NHS England published Clinical Commissioning Policy: Anakinra for<unk>  <unk>  for adults and children in all ages, allowing Anakinra (a modified recombinant interleukin 1 receptor antagonist) to be used in the treatment of<unk> .
Hemophagocytic lymphohistiocytosis
Diffuse infiltrative lymphocytosis syndrome
Congenital self-healing reticulohistiocytosis
Thymoma with immunodeficiency
Langerhans cell histiocytosis
Blastic plasmacytoid dendritic cell neoplasm
Hereditary pyropoikilocytosis
Angioimmunoblastic T-cell lymphoma